Donna E. Hogge
Affiliations: | University of British Columbia, Vancouver, Vancouver, BC, Canada |
Area:
Cell Biology, OncologyGoogle:
"Donna Hogge"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lin TL, Rizzieri DA, Ryan DH, et al. (2021) Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. Blood Advances. 5: 1719-1728 |
| England JT, Saini L, Hogge D, et al. (2020) Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort. Clinical Lymphoma, Myeloma & Leukemia |
| Lancet JE, Uy GL, Newell LF, et al. (2020) Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Clinical Oncology. 38: 7510-7510 |
| Ryan DH, Newell LF, Ritchie EK, et al. (2020) Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis Biology of Blood and Marrow Transplantation. 26: S9-S10 |
| Kolitz JE, Strickland SA, Cortes JE, et al. (2019) Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia & Lymphoma. 1-10 |
| Kodad SG, Sutherland H, Limvorapitak W, et al. (2019) Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center. Clinical Lymphoma, Myeloma & Leukemia |
| Matza LS, Deger KA, Howell TA, et al. (2019) Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML). Journal of Medical Economics. 1 |
| Kolitz JE, Ryan DH, Newell LF, et al. (2019) Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy Blood. 134: 3856-3856 |
| Alahwal H, Song K, Yu M, et al. (2019) Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant. Clinical Lymphoma Myeloma and Leukemia. 19: e42-e43 |
| Lin TL, Ryan DH, Ritchie EK, et al. (2019) Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission Blood. 134: 1316-1316 |